Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
暂无分享,去创建一个
Didier Frappaz | R. Stupp | C. Marosi | D. Frappaz | R. Henriksson | H. Schultz | M. Hegi | B. Lhermitte | U. Abacıoğlu | Roger Stupp | Monika E Hegi | Benoit Lhermitte | Björn Tavelin | Christine Marosi | Roger Henriksson | A. Malmström | J. Rosell | Ufuk Abacioglu | Johan Rosell | Annika Malmström | Bjørn Henning Grønberg | Henrik Schultz | B. Grønberg | B. Tavelin | U. Abacioglu | Johan Rosell
[1] G. Reifenberger,et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[2] F. Ducray,et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Robert N. Anderson,et al. Annual Report to the Nation on the Status of Cancer, 1975–2007, Featuring Tumors of the Brain and Other Nervous System , 2011, Journal of the National Cancer Institute.
[4] K. Franz,et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] U. Tirelli,et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. , 2010, Archives of gerontology and geriatrics.
[6] H. Zentgraf,et al. Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.
[7] A. Brandes,et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma , 2009, Cancer.
[8] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[9] M. Delorenzi,et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. , 2008, The Journal of molecular diagnostics : JMD.
[10] J. Cairncross,et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme , 2008, Journal of Neuro-Oncology.
[11] J. Debus,et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. , 2008, International journal of radiation oncology, biology, physics.
[12] V. Tombolini,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients , 2008, Journal of Neuro-Oncology.
[13] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[14] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[15] F. Bosman,et al. An Agarose Matrix Facilitates Sectioning of Tissue Microarray Blocks , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[16] Lena Damber,et al. Registrering av primära hjärntumörer mått på nationell vårdkvalitet. Regionala skillnader avslöjade. , 2007 .
[17] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[18] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[19] K. Hoang-Xuan,et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations , 2004, Cancer.
[20] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Osoba,et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires , 1996, Quality of Life Research.
[22] L. Recht,et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas , 2003, Cancer.
[23] D. Osoba,et al. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. , 2000, European journal of cancer.
[24] D. Osoba,et al. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[26] A. Gregor,et al. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma , 1994 .
[27] J. Cairncross,et al. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. , 1994, International journal of radiation oncology, biology, physics.
[28] C. Kennard,et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.
[29] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .